| Mon, Nov 23, 2009 |
| • |
Valeant Pharma begins selling generic IBS drug
AP (Mon 3:46pm)
|
| • |
[$$] Valeant Shares Fall Ill
at Barrons.com (Mon 2:03pm)
|
| • |
Barron's Magazine First Read: Dividends, VRX, DISCA
at Barrons.com (Mon 10:00am)
|
| • |
Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
PRNewswire (Mon 8:01am)
|
| Sun, Nov 22, 2009 |
| • |
Valeant may fall if new drug disappoints-Barron's
at Reuters (Sun, Nov 22)
|
| Sat, Nov 21, 2009 |
| • |
This Weekend's Barron's: Dividend Paying Stocks; BB&T Is the Banking Belle of the South; Is There Any Hope for Atlantic City
at Barrons.com (Sat, Nov 21)
|
| • |
[$$] Hot Drug Stock in Need of a Chill Pill
at Barrons.com (Sat, Nov 21)
|
| Wed, Nov 18, 2009 |
| • |
Drugmaker Reinvents Itself And Expands Footprint Internationally
Investor's Business Daily (Wed, Nov 18)
|
| Wed, Nov 11, 2009 |
| • |
Big Value in Valeant
RealMoney by TheStreet.com (Wed, Nov 11)
|
| Tue, Nov 10, 2009 |
| • |
VALEANT PHARMACEUTICALS INTERNATIONAL Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal
EDGAR Online (Tue, Nov 10)
|
| • |
UBS Research Equity Analyst Picks Top Stocks In Large Cap Biotech Sector
Wall Street Transcript (Tue, Nov 10)
|
| Fri, Nov 6, 2009 |
| • |
VALEANT PHARMACEUTICALS INTERNATIONAL Financials
EDGAR Online Financials (Fri, Nov 6)
|
| Tue, Nov 3, 2009 |
| • |
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD)
PRNewswire (Tue, Nov 3)
|
| Mon, Nov 2, 2009 |
| • |
Valeant Pharmaceuticals International Q3 2009 Earnings Call Transcript
at Seeking Alpha (Mon, Nov 2)
|
| • |
Valeant: It Turns Out that Wrinkles Are Worth Quite a Lot
at Seeking Alpha (Mon, Nov 2)
|
| • |
Valeant 3Q net income down, results top forecast
AP (Mon, Nov 2)
|
| • |
Valeant Pharmaceuticals International Earnings Call scheduled for 10:00 am ET today
CCBN (Mon, Nov 2)
|
| • |
UPDATE - Valeant Q3 beats estimates, raises '09 profit view
at Reuters (Mon, Nov 2)
|
| • |
VALEANT PHARMACEUTICALS INTERNATIONAL Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Mon, Nov 2)
|
| • |
Valeant Pharmaceuticals Reports Third Quarter Financial Results - Revenue up 31%, 45% at constant exchange rates- GAAP EPS $0.45, Cash EPS $0
PRNewswire (Mon, Nov 2)
|
| Older Headlines |
|
|
|
|
Help
Headlines
